Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD]

Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD]

Saved in:

Bibliographic Details
Main Authors:	Tushar Tarun, Otis M. Davis, Sai N. Ghanta, Nishank Jain
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924016140
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Challenging the Restrictive Approach: Reconsidering Sodium-Glucose Transport Protein 2 Inhibitor Use in CKD
by: Ozant Helvaci, et al.
Published: (2024-06-01)

Updates on New Therapies for Patients with CKD
by: Tushar Tarun, et al.
Published: (2024-01-01)

Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety
by: Bing Zhang, et al.
Published: (2025-07-01)

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-02-01)

Author Correction: SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-04-01)

SGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges
by: Taimin Luo, et al.
Published: (2025-07-01)

Protein restriction in CKD: an outdated strategy in the modern era
by: Abdullah Bawazir, et al.
Published: (2025-02-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia
by: Amit Joharapurkar, et al.
Published: (2024-10-01)

Role of SGLT2 inhibitors in the treatment of visceral obesity
by: M. A. Druzhilov, et al.
Published: (2021-02-01)

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01)

Osteomyelitis Pubis After Initiation of an SGLT2 Inhibitor
by: Adriana Nadeau, et al.
Published: (2022-10-01)

The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis
by: Chung-Shu Lee, et al.
Published: (2025-05-01)

Advances in the mechanism of action of SGLT2 inhibitors on the kidney
by: JI Ying, et al.
Published: (2020-01-01)

A study on the pharmacovigilance of various SGLT-2 inhibitors
by: Yanwen Dong, et al.
Published: (2025-01-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Yeavering Reconsidered
by: John T. Smith
Published: (2015-05-01)

Testosterone-induced erythrocytosis: addressing the challenge of metabolic syndrome and widely prescribed SGLT2-inhibitor drugs
by: Federica Tramontana, et al.
Published: (2025-06-01)

A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD
by: Jheng-Yan Wu, et al.
Published: (2025-08-01)

Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
by: Linda Piras, et al.
Published: (2024-11-01)

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
by: Mohamed Alhemeiri, et al.
Published: (2022-01-01)

A Review on the Relationship between SGLT2 Inhibitors and Cancer
by: Hao-Wen Lin, et al.
Published: (2014-01-01)

Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs
by: Divya Rajagopal, et al.
Published: (2024-10-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
by: Filip Rolski, et al.
Published: (2025-02-01)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024-11-01)

Reconsidering antihypertensive choice
by: Andy Gray
Published: (2003-05-01)

Reconsidering earthquake scaling
by: J. Gomberg, et al.
Published: (2016-06-01)

Reconsidering Community Renovation:
by: Yasunori Miyawaki
Published: (2025-01-01)

Regional prices reconsidered
by: David Hearne, et al.
Published: (2025-12-01)

Reconsidering the Library Week
by: Erol Yılmaz
Published: (2013-11-01)

Reconsidering Educational Research
by: Iva Stuchlíková, et al.
Published: (2017-02-01)

SGLT2 inhibitors across various patient populations in the era of precision medicine: the multidisciplinary team approach
by: Patrick McLean, et al.
Published: (2025-07-01)

The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients
by: Jia-Yuh Sheu, et al.
Published: (2024-11-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism
by: Brett W. Sperry, MD, et al.
Published: (2025-08-01)

Progress in studies on renal effects and molecular mechanism of SGLT-2 inhibitors
by: XING Bei, et al.
Published: (2020-01-01)

Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis
by: Nikita Ermolaev, et al.
Published: (2025-03-01)

Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors
by: Selin Genc, et al.
Published: (2024-11-01)

Is it Time to Expand the Use of SGLT2 Inhibitors in Kidney Transplant Recipients?
by: Kajaree Giri, et al.
Published: (2025-03-01)